首页> 外文期刊>Journal of biomedical materials research. Part B, Applied biomaterials. >A prospective randomized 14-year follow-up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors
【24h】

A prospective randomized 14-year follow-up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors

机译:生物活性玻璃和自体骨作为良性骨肿瘤替代骨移植物的前瞻性随机14年随访研究

获取原文
获取原文并翻译 | 示例
           

摘要

A prospective randomized long-term follow-up study of bioactive glass (BG)-S53P4 and autogenous bone (AB) used as bone graft substitutes in benign bone tumor surgery during 1993-1997 was conducted. Twenty-one patients (11 in the BG group, 10 in the AB group) participated in a 14-year follow-up. X-rays and MRI scans were obtained, and in the BG group, CT scans were also performed. In the BG group, the filled cavity had a dense appearance on X-ray. MRI showed a mainly or partly fatty bone marrow, and in the large bone tumor group, remnants of glass granuleswere also observed. Increased cortical thicknesswas seen in nonossifying fibromas and enchondromas. BG-S53P4 is a safe and well-tolerated bone substitute with good long-term results. BG-S53P4 does not disturb the growth of bone in children.
机译:进行了一项前瞻性随机长期随访研究,研究对象是1993-1997年间在良性骨肿瘤手术中用作骨移植替代物的生物活性玻璃(BG)-S53P4和自体骨(AB)。 21例患者(BG组11例,AB组10例)参加了14年的随访。获得了X射线和MRI扫描,在BG组中,还进行了CT扫描。在BG组中,填充的腔在X射线上具有密集的外观。 MRI显示主要或部分为脂肪的骨髓,在大型骨肿瘤组中,还观察到玻璃颗粒的残留。在非骨化性纤维瘤和内生软骨瘤中可见皮质厚度增加。 BG-S53P4是一种安全且耐受良好的骨替代品,具有良好的长期效果。 BG-S53P4不会干扰儿童骨骼的生长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号